Conceptual basis for focal therapy in prostate cancer

Journal of Endourology

Volumn 24, Issue 5, 2010, Pages 811-818

  Lecornet, Emilie ^a,b   Ahmed, Hashim Uddin ^a   Moore, Caroline M ^a   Emberton, Mark ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CONCEPT ANALYSIS; CONTROLLED STUDY; CRYOTHERAPY; HEALTH CARE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IMPOTENCE; INCONTINENCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PHOTODYNAMIC THERAPY; POPULATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PSYCHOLOGICAL ASPECT; RADIOFREQUENCY ABLATION; SCREENING; TECHNOLOGY; TOXICITY; TUMOR BIOPSY;

BIOPSY, NEEDLE; CATHETER ABLATION; CRYOTHERAPY; HUMANS; HYPERTHERMIA, INDUCED; MALE; PHOTOCHEMOTHERAPY; PROSTATIC NEOPLASMS; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 77952568191     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2009.0654     Document Type: Article

References (89)

1. Umbehr M, Bachmann LM, Held U, et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: A systematic review and meta-analysis. Eur Urol 2009;55:575-590.
2. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-1984. (Pubitemid 40638368)
3. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:1144-1154.
4. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009;302:1557-1564.
5. Cahlon O, Hunt M, Zelefsky MJ. Intensity-modulated radiation therapy: Supportive data for prostate cancer. Semin Radiat Oncol 2008;18:48-57.
6. Sharma NL, Shah NC, Neal DE. Robotic-assisted laparoscopic prostatectomy. Br J Cancer 2009;101:1491-1496.
7. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007;4:632-642.
8. Lindner U, Trachtenberg J. Focal therapy for localized prostate cancer-choosing the middle ground. Can Urol Assoc J 2009;3:333-335.
9. Sartor AO, Hricak H, Wheeler TM, et al. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology 2008;72(6 Suppl):S12-S24.
10. Ahmed HU, Emberton M. Active surveillance and radical therapy in prostate cancer: Can focal therapy offer the middle way? World J Urol 2008;26:457-467.
11. Klotz L. Active surveillance for prostate cancer: For whom? J Clin Oncol 2005;23:8165-8169.
12. Freedland SJ, Aronson WJ, Terris MK, et al. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: Results from SEARCH database. J Urol 2003;169:2136-2141.
13. Amin M, Boccon-Gibod L, Egevad L, et al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl 2005; (216):20-33.
14. Antunes AA, Srougi M, Dall'Oglio MF, Crippa A, Campagnari JC, Leite KR. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy. BJU Int 2005;96:1258-1263.
15. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005;23:6992-6998.
16. Fujita K, Landis P, McNeil BK, Pavlovich CP. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009;182:2664-2669.
17. Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001;166:1804-1810.
18. Galbraith ME, Ramirez JM, Pedro LW. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol Nurs Forum 2001;28: 551-560.
19. Litwin MS, Lubeck DP, Spitalny GM, Henning JM, Carroll PR. Mental health in men treated for early stage prostate carcinoma: A posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer 2002;95:54-60.
20. Dale W, Bilir P, Han M, Meltzer D. The role of anxiety in prostate carcinoma: A structured review of the literature. Cancer 2005;104:467-478.
21. Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int 2007;100:544-551.
22. Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 2007;178(3 Pt 1):826- 831; discussion 831-832.
23. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 2007;100:540-543.
24. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006;24:46-50. (Pubitemid 43097357)
25. Black P. There is no role for focal therapy in prostate cancer. Can Urol Assoc J 2009;3:331-332.
26. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291: 2713-2719.
27. Hegarty NJ, Kaouk JH. Radical prostatectomy: A comparison of open, laparoscopic and robot-assisted laparoscopic techniques. Can J Urol 2006;13 Suppl 1:56-61.
28. Khoo VS. Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clin Oncol (R Coll Radiol) 2005;17:560-571.
29. Mouraviev V, Mayes JM, Madden JF, Sun L, Polascik TJ. Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Technol Cancer Res Treat 2007;6: 91-95.
30. Polascik TJ, Mouraviev V. Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urology 2009;74:726-730.
31. Mouraviev V, Mayes JM, Polascik TJ. Pathological background and its clinical implications for focal therapy of early detected prostate cancer. Nat Clin Pract Urol (In press).
32. Tsivian M, Kimura M, Sun L, Mouraviev V, Mayes JM, Polascik TJ. Predicting unilateral prostate cancer on routine diagnostic biopsy: Sextant vs extended. BJU Int 2009.
33. Jayram G, Eggener SE. Patient selection for focal therapy of localized prostate cancer. Curr Opin Urol 2009;19:268-273.
34. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007;110:906-910.
35. Tareen B, Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS. Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. Urology 2009;73: 351-354; discussion 354-355.
36. De Laet K, de la Taille A, Ploussard G, et al. Predicting tumour location in radical prostatectomy specimens: Samepatient comparisons of 21-sample versus sextant biopsy. BJU Int 2009;104:616-620.
37. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med 2009;361:1704-1706.
38. Villers A, Lemaitre L, Haffner J, Puech P. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: Implications for focal therapy and active surveillance. Curr Opin Urol 2009;19:274-282.
39. Nelson BA, Shappell SB, Chang SS, et al. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 2006;97:1169-1172.
40. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992;70:2313-2318.
41. Onik G. Rationale for a "male lumpectomy," a prostate cancer targeted approach using cryoablation: Results in 21 patients with at least 2 years of follow-up. Cardiovasc Intervent Radiol 2008;31:98-106.
42. Ellis DS, Manny TB Jr., Rewcastle JC. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: Initial results. Urology 2007;70(6 Suppl):9-15.
43. Lindner U, Weersink RA, Haider MA, et al. Image guided photothermal focal therapy for localized prostate cancer: Phase I trial. J Urol 2009;182:1371-1377.
44. de Senneville BD, Mougenot C, Moonen CT. Real-time adaptive methods for treatment of mobile organs by MRIcontrolled high-intensity focused ultrasound. Magn Reson Med 2007;57:319-330.
45. de Senneville BD, Mougenot C, Quesson B, Dragonu I, Grenier N, Moonen CT. MR thermometry for monitoring tumor ablation. Eur Radiol 2007;17:2401-2410.
46. McNichols RJ, Gowda A, Kangasniemi M, Bankson JA, Price RE, Hazle JD. MR thermometry-based feedback control of laser interstitial thermal therapy at 980 nm. Lasers Surg Med 2004;34:48-55.
47. Mougenot C, Quesson B, de Senneville BD, et al. Threedimensional spatial and temporal temperature control with MR thermometry-guided focused ultrasound (MRgHIFU). Magn Reson Med 2009;61:603-614.
48. Iczkowski KA, Hossain D, Torkko KC, et al. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology 2008;71:1166-1171.
49. Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: Lack of significance of secondary cancers. J Urol 2003;170(2 Pt 1):459-463.
50. Harnden P, Naylor B, Shelley MD, Clements H, Coles B, Mason MD. The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression? A systematic review and meta-analysis. Cancer 2008;112:971-981. (Pubitemid 351304580)
51. Bostwick DG, Waters DJ, Farley ER, et al. Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology 2007;70(6 Suppl):42-44.
52. Eggener SE, Scardino PT, Carroll PR, et al. Focal therapy for localized prostate cancer: A critical appraisal of rationale and modalities. J Urol 2007;178:2260-2267.
53. Turkbey B, Pinto PA, Choyke PL. Imaging techniques for prostate cancer: Implications for focal therapy. Nat Rev Urol 2009;6:191-203.
54. Yang JC, Tang J, Li J, Luo Y, Li Y, Shi H. Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels. Acad Radiol 2008;15:1291-1297.
55. Tang J, Yang JC, Li Y, Li J, Shi H. Peripheral zone hypoechoic lesions of the prostate: Evaluation with contrast-enhanced gray scale transrectal ultrasonography. J Ultrasound Med 2007;26:1671-1679.
56. Halpern EJ, Ramey JR, Strup SE, Frauscher F, McCue P, Gomella LG. Detection of prostate carcinoma with contrastenhanced sonography using intermittent harmonic imaging. Cancer 2005;104:2373-2383.
57. Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: Current approaches and new developments. AJR Am J Roentgenol 2009;192:1471-1480.
58. Atri M, Gertner MR, Haider MA, Weersink RA, Trachtenberg J. Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer. Can Urol Assoc J 2009;3: 125-130.
59. Braeckman J, Autier P, Soviany C, et al. The accuracy of transrectal ultrasonography supplemented with computeraided ultrasonography for detecting small prostate cancers. BJU Int 2008;102:1560-1565.
60. Salomon G, Kollerman J, Thederan I, et al. Evaluation of prostate cancer detection with ultrasound real-time elastography: A comparison with step section pathological analysis after radical prostatectomy. Eur Urol 2008;54:1354-1362.
61. Turpen R, Rosser CJ. Focal therapy for prostate cancer: Revolution or evolution? BMC Urol 2009;9:2.
62. Ravizzini G, Turkbey B, Kurdziel K, Choyke PL. New horizons in prostate cancer imaging. Eur J Radiol 2009;70: 212-226.
63. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241: 449-458.
64. Jackson AS, Reinsberg SA, Sohaib SA, et al. Dynamic contrast- enhanced MRI for prostate cancer localization. Br J Radiol 2009;82:148-156.
65. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: Correlation with radical prostatectomy findings. J Urol 2006;176(6 Pt 1):2432-2437.
66. Girouin N,Mege-Lechevallier F, Tonina SenesA, et al. Prostate dynamic contrast-enhancedMRIwith simple visual diagnostic criteria: Is it reasonable? Eur Radiol 2007;17:1498-1509.
67. Yoshizako T, Wada A, Hayashi T, et al. Usefulness of diffusion- weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol 2008;49:1207-1213.
68. Kelloff GJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: Role of imaging. AJR Am J Roentgenol 2009; 192:1455-1470.
69. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis- correlation with biopsy and histopathology. J Magn Reson Imaging 2006;24:108-113.
70. Shimofusa R, Fujimoto H, Akamata H, et al. Diffusionweighted imaging of prostate cancer. J Comput Assist Tomogr 2005;29:149-153.
71. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: The clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25:146-152.
72. Weinreb JC, Blume JD, Coakley FV, et al. Prostate cancer: Sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009;251:122-133.
73. Ahmed HU, Kirkham A, Arya M, et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009;6:197-206.
74. Krieger A, Susil RC, Menard C, et al. Design of a novel MRI compatible manipulator for image guided prostate interventions. IEEE Trans Biomed Eng 2005;52:306-313.
75. Onik G, Barzell W. Transperineal 3D mapping biopsy of the prostate: An essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol 2008;26:506-510.
76. Tareen B, Godoy G, Sankin A, Temkin S, Lepor H, Taneja SS. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer? BJU Int 2009;104:195-199.
77. Bolenz C, Gierth M, Grobholz R, et al. Clinical staging error in prostate cancer: Localization and relevance of undetected tumour areas. BJU Int 2009;103:1184-1189.
78. Crawford ED, Wilson SS, Torkko KC, et al. Clinical staging of prostate cancer: A computer-simulated study of transperineal prostate biopsy. BJU Int 2005;96:999-1004.
79. Lambert EH, Bolte K, Masson P, Katz AE. Focal cryosurgery: Encouraging health outcomes for unifocal prostate cancer. Urology 2007;69:1117-1120.
80. Bahn DK, Silverman P, Lee F, Sr., Badalament R, Bahn ED, Rewcastle JC. Focal prostate cryoablation: Initial results show cancer control and potency preservation. J Endourol 2006;20:688-692.
81. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. The "male lumpectomy": Focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year followup. Urol Oncol 2008;26:500-505.
82. Ritch CR, Katz AE. Prostate cryotherapy: Current status. Curr Opin Urol 2009;19:177-181.
83. Ahmed HU, Moore C, Emberton M. Minimally-invasive technologies in uro-oncology: The role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol 2009;18:219-232.
84. Ritch CR, Katz AE. Update on cryotherapy for localized prostate cancer. Curr Urol Rep 2009;10:206-211.
85. Ahmed HU, Zacharakis E, Dudderidge T, et al. High-intensity- focused ultrasound in the treatment of primary prostate cancer: The first UK series. Br J Cancer 2009;101:19-26.
86. Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 2008; 38:192-199. (Pubitemid 351419743)
87. Emberton M. VTP for men with prostate cancer-early results. J Endourol 2008;22:3.
88. Marberger M, Carroll PR, Zelefsky MJ, et al. New treatments for localized prostate cancer. Urology 2008;72(6 Suppl):S36-S43.
89. Polascik TJ, Mayes JM, Mouraviev V. Nerve-sparing focal cryoablation of prostate cancer. Curr Opin Urol 2009;19:182-187.